ITCI is moving mostly horizontally lately, and there's definite room for downside to its channel bottom around 10.40, so this is a risky play. However, a large stock purchase a couple days ago by one of the board of directors triggered a large volume of bullish option activity. Possibly the director purchased stock in anticipation of forthcoming clinical trial results that he expects to be positive. Watch this one closely and look for an opportunity to buy nearer the channel bottom. Alternatively, wait for upside channel breakout.
ITCI has generally poor analyst ratings and negative earnings. However, it's made progress toward profitability and generally delivered earnings beats in recent quarters. It next reports on August 6.